<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01095588</url>
  </required_header>
  <id_info>
    <org_study_id>TA-016</org_study_id>
    <nct_id>NCT01095588</nct_id>
  </id_info>
  <brief_title>Study the Effect of Avanafil on the Pharmacodynamics and Pharmacokinetics of Warfarin in Healthy Male Subjects</brief_title>
  <official_title>A Phase I, Single-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Arm Study of the Effects of Avanafil on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VIVUS, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VIVUS, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to look into the effect of avanafil on blood levels of warfarin and to&#xD;
      investigate its effect on prothrombin time/international normalized ratio (INR) in healthy&#xD;
      men.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is a single-centre, double-blind, randomized, placebo-controlled, 2-way crossover&#xD;
      drug interaction study with at least a 21-day washout period.&#xD;
&#xD;
      Each subject will participate in two sessions in which they will be randomized to receive&#xD;
      either 200 mg of avanafil or matching placebo for 9 days. On Day 3 of each period, subjects&#xD;
      will receive a single dose of warfarin (25 mg). Following the warfarin dose, pharmacokinetic&#xD;
      and pharmacodynamic sampling will be taken over a period of 7 days. Subjects will be&#xD;
      discharged on Day 10 following the end-of-period evaluation. There will be a washout of at&#xD;
      least 21 days between the warfarin doses. The study medications will be administered with 240&#xD;
      mL of water following an overnight fast of at least 10 hours.&#xD;
&#xD;
      Blood samples (3 mL) for the assessment of R- and S-warfarin concentrations in plasma will be&#xD;
      drawn on Day 3 prior to warfarin administration and 0.5, 1, 1.5, 2, 4, 6, 9, 12, 24, 48, 72,&#xD;
      96, 120, 144, and 168 hours after the warfarin administration.&#xD;
&#xD;
      Blood samples (3 mL) for the assessment of avanafil and/or metabolite concentrations will be&#xD;
      drawn on Day 3 prior to avanafil (or placebo) administration and at 0.5, 1, and 2 hours&#xD;
      post-dose.&#xD;
&#xD;
      Blood samples (4.5 mL) for the assessment of prothrombin time (PT) and international&#xD;
      normalized ratio (INR) will be drawn at screening, check-in, on Day 3 prior to warfarin&#xD;
      administration and at 6, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours post-dose.&#xD;
&#xD;
      Blood samples (4.5 mL) for collagen-induced platelet aggregation will be drawn on Day 3 prior&#xD;
      to warfarin administration and at 1, 4, 6, 12, and 24 hours post-dose.&#xD;
&#xD;
      A blood sample (8.5 mL) for VKORC1 and CYP2C9 genotyping will be drawn at the check-in for&#xD;
      Period 1.&#xD;
&#xD;
      The overall blood volume required for this study (assuming direct venipuncture for each&#xD;
      sample) will be approximately 446 mL.&#xD;
&#xD;
      All subjects will be confined at the Clinical Research Unit starting in on Day -2 for diet&#xD;
      equilibration and will remain confined for approximately 24 hours following the last study&#xD;
      drug administration on Day 9.&#xD;
&#xD;
      Adverse events, laboratory evaluations, electrocardiogram, physical examination, and vital&#xD;
      signs will be assessed at various times during the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics - PK parameters AUC, C-max and t-max of R-and S-warfarin</measure>
    <time_frame>24 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics - Prothrombin time, INR values, and area under effect-time curve (AUEC) of prothrombin and INR on days 14 and 15</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Avanafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>200 mg Avanafil</intervention_name>
    <description>2 X 100mg tablets avanafil</description>
    <arm_group_label>Avanafil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adult male subjects,&#xD;
&#xD;
          -  21 to 45 years of age,&#xD;
&#xD;
          -  must be medically healthy with no clinically significant screening results.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history or clinical evidence of clinically relevant cardiovascular (including&#xD;
             thromboembolic disorders), hepatic, renal, hematological, endocrine, pulmonary,&#xD;
             gastrointestinal, psychiatric or neurological impairment;&#xD;
&#xD;
          -  any clinically significant laboratory abnormalities as judged by the investigator;&#xD;
&#xD;
          -  systolic blood pressure &lt; 90 or &gt;120 mmHg;&#xD;
&#xD;
          -  diastolic blood pressure &lt; 50 or &gt; 90 mmHg;&#xD;
&#xD;
          -  allergy to or previous adverse events with PDE5 inhibitors, warfarin or their&#xD;
             constituents;&#xD;
&#xD;
          -  use of prescription or over-the-counter drugs that are known to interfere with&#xD;
             metabolism by the cytochrome P450 3A4 enzyme within 30 days of screening;&#xD;
&#xD;
          -  use of any investigational drug within 30 days of screening; use of any prescription&#xD;
             or over-the-counter drugs or herbal remedies within 14 days of screening;&#xD;
&#xD;
          -  history of alcohol or drug abuse within 18 months, history of smoking within 6 months;&#xD;
&#xD;
          -  positive urine alcohol and drug test;&#xD;
&#xD;
          -  positive serum cotinine test;&#xD;
&#xD;
          -  positive serology for HIV, HCV, HBsAg.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shiyin Yee, PhD</last_name>
    <role>Study Director</role>
    <affiliation>VIVUS, Inc.</affiliation>
  </overall_official>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>January 6, 2009</study_first_submitted>
  <study_first_submitted_qc>March 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2010</study_first_posted>
  <last_update_submitted>January 5, 2011</last_update_submitted>
  <last_update_submitted_qc>January 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Wesley Day, VP Clinical</name_title>
    <organization>Vivus, Inc.</organization>
  </responsible_party>
  <keyword>ED</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

